Evidence map›Paper›PMID 41743162›Full record

ArticleMaterials today. Bio2026

Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment

Nuerbiye Aobulikasimu, Lele Fang, Aidiresi Maimaitiyiming, Dilimureti Kasimu, Adila Aipire, Weilan Wang, Zhongxiong Fan, Jinyao Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nuerbiye AobulikasimuXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, 830017, China.
Lele FangXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, 830017, China.
Aidiresi MaimaitiyimingThe First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830017, China.
Dilimureti KasimuXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, 830017, China.
Adila AipireXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, 830017, China.
Weilan WangXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, 830017, China.
Zhongxiong FanSchool of Pharmaceutical Sciences, Institute of Materia Medica, Xinjiang University, Urumqi, 830017, China.
Jinyao LiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, 830017, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer, a highly lethal gynecological malignancy with high recurrence rates and low survival, poses significant treatment challenges. While immunotherapy, particularly dendritic cell (DC) vaccines, boosts immune responses, its clinical efficacy is limited by poor antigen presentation and weak lymph node targeting. To address this, we develop a novel biomimetic nanovaccine (GA-NPs@DCV) using cell membrane-coated nanoparticles that incorporate the natural anti-tumor agent galangin (GA) and ovarian tumor-associated antigens (TAAs). GA-NPs@DCV features the antigen-presenting functions of DCs and utilizes GA to induce tumor immunogenic cell death (ICD), which not only endows the vaccine with abundantly processed specific TAAs, but also ensures robust homing capability to lymph nodes and the tumor microenvironment. Interestingly, in OT-I/OT-II transgenic mice, GA-NPs@DCV enhances the proliferation of CD8

Indexed as

Anti-ovarian cancerDendritic cells vaccineGalanginStat3/IDO1/AhR signaling axisTumor immune microenvironment

Identifiers

PMID41743162
PMCPMC12930037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.